 - Patients must have a serum testosterone 150 ngdL at the time of study entry. Patients may have received previous castrating hormonal therapy or anti-androgens, provided that the testosterone level is 150 ngdL at the time of study entry. Prior chemotherapy is also allowed as long as the requirements for adequate organ and marrow function are met. 